Genomic Amplifications Identified by Circulating Tumor DNA Analysis Guide Prognosis in Metastatic Castration-resistant Prostate Cancer

Overview

Journal Front Oncol

Specialty Oncology

Date 2024 Mar 7

PMID 38450313

Authors

Toros A Dincman

Joseph A Q Karam

Antonio Giordano

Hong Li

Leylah M Drusbosky

Theodore S Gourdin

Philip H Howe

Michael B Lilly

Affiliations

Soon will be listed here.

Abstract

Purpose: Analysis of circulating tumor DNA (ctDNA) in patients with metastatic prostate cancer (mPC) provides an opportunity to identify and monitor genomic alterations during a patient's treatment course. We evaluated whether the presence of specific gene amplifications (GAs) and plasma copy number (PCN) alterations are associated with disease features.

Methods: This is a single-institution retrospective study of patients with mPC who underwent ctDNA profiling using Guardant360 (Guardant Health Inc.). This test identifies single nucleotide variants (SNVs) and GAs of select genes by next-generation sequencing. A total of 155 men with mPC were studied. Patients were stratified by GA status. The Kaplan-Meier method and multivariate cox regression models were used to estimate overall survival (OS) or failure-free survival (FFS) from either the date of GA detection or the initiation of systemic therapy. The chi-square test was used to evaluate associations between clinical factors and GAs.

Results: The presence of liver and/or lung metastases was associated with GAs of , and . Survival analyses were completed on a subset of 83 patients with metastatic castration-resistant prostate cancer (mCRPC). Median OS was improved in patients with 1 GA compared to patients with ≥2 GAs, whether determined from the date of initial GA(s) detection (14.9 mo vs. 8.9 mo) or date of therapy initiation nearest to GA detection (16.7 mo vs. 9.0 mo). Patients without GAs had not reached median OS. Patients with androgen receptor () GA only were also found to have better median OS compared to patients with GA plus at least one other additional GA (19.3 mo vs. 8.9 mo). Patients with GA had significantly lower median OS compared to patients with GAs that did not have a GA (5.9 mo vs. 16.0 mo). In patients with and/or GA(s), median OS improved in those with reduced or PCN during therapy compared to those without such a reduction (25.1 mo vs. 15.9 mo).

Conclusions: The association of select GAs with survival provides an additional tool for assessing mCRPC prognosis and informing management. Serial monitoring of ctDNA GAs is also useful to guide prognosis and therapeutic response.

References

Zhang Q, Luo J, Wu S, Si H, Gao C, Xu W . Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade. Cancer Discov. 2020; 10(12):1842-1853. PMC: 8358981. DOI: 10.1158/2159-8290.CD-20-0047. View

Sonpavde G, Agarwal N, Pond G, Nagy R, Nussenzveig R, Hahn A . Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer. Cancer. 2019; 125(9):1459-1469. DOI: 10.1002/cncr.31959. View

Mehra N, Dolling D, Sumanasuriya S, Christova R, Pope L, Carreira S . Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA). Eur Urol. 2018; 74(3):283-291. PMC: 6090941. DOI: 10.1016/j.eururo.2018.02.013. View

Yang F, Zhang Y, Ressler S, Ittmann M, Ayala G, Dang T . FGFR1 is essential for prostate cancer progression and metastasis. Cancer Res. 2013; 73(12):3716-24. PMC: 3686853. DOI: 10.1158/0008-5472.CAN-12-3274. View

Lanman R, Mortimer S, Zill O, Sebisanovic D, Lopez R, Blau S . Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA. PLoS One. 2015; 10(10):e0140712. PMC: 4608804. DOI: 10.1371/journal.pone.0140712. View

Gourdin T, Sonpavde G . Utility of cell-free nucleic acid and circulating tumor cell analyses in prostate cancer. Asian J Androl. 2018; 20(3):230-237. PMC: 5952476. DOI: 10.4103/aja.aja_1_18. View

Miller E, You S, Cadaneanu R, Kim M, Yoon J, Liu S . Chromosomal instability in untreated primary prostate cancer as an indicator of metastatic potential. BMC Cancer. 2020; 20(1):398. PMC: 7204307. DOI: 10.1186/s12885-020-06817-1. View

Leuva H, Sigel K, Zhou M, Wilkerson J, Aggen D, Anna Park Y . A novel approach to assess real-world efficacy of cancer therapy in metastatic prostate cancer. Analysis of national data on Veterans treated with abiraterone and enzalutamide. Semin Oncol. 2019; 46(4-5):351-361. DOI: 10.1053/j.seminoncol.2019.11.004. View

Epstein J, Zelefsky M, Sjoberg D, Nelson J, Egevad L, Magi-Galluzzi C . A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score. Eur Urol. 2015; 69(3):428-35. PMC: 5002992. DOI: 10.1016/j.eururo.2015.06.046. View

10.

Liu J, Chen G, Liu Z, Liu S, Cai Z, You P . Aberrant FGFR Tyrosine Kinase Signaling Enhances the Warburg Effect by Reprogramming LDH Isoform Expression and Activity in Prostate Cancer. Cancer Res. 2018; 78(16):4459-4470. PMC: 6095720. DOI: 10.1158/0008-5472.CAN-17-3226. View

11.

Pezaro C, Omlin A, Lorente D, Nava Rodrigues D, Ferraldeschi R, Bianchini D . Visceral disease in castration-resistant prostate cancer. Eur Urol. 2013; 65(2):270-273. PMC: 4881819. DOI: 10.1016/j.eururo.2013.10.055. View

12.

Viswanathan S, Ha G, Hoff A, Wala J, Carrot-Zhang J, Whelan C . Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing. Cell. 2018; 174(2):433-447.e19. PMC: 6046279. DOI: 10.1016/j.cell.2018.05.036. View

13.

Taylor A, Shih J, Ha G, Gao G, Zhang X, Berger A . Genomic and Functional Approaches to Understanding Cancer Aneuploidy. Cancer Cell. 2018; 33(4):676-689.e3. PMC: 6028190. DOI: 10.1016/j.ccell.2018.03.007. View

14.

Grist E, Friedrich S, Brawley C, Mendes L, Parry M, Ali A . Accumulation of copy number alterations and clinical progression across advanced prostate cancer. Genome Med. 2022; 14(1):102. PMC: 9442998. DOI: 10.1186/s13073-022-01080-4. View

15.

Fizazi K, Foulon S, Carles J, Roubaud G, McDermott R, Flechon A . Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design. Lancet. 2022; 399(10336):1695-1707. DOI: 10.1016/S0140-6736(22)00367-1. View

16.

Odegaard J, Vincent J, Mortimer S, Vowles J, Ulrich B, Banks K . Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and Plasma-Based Methodologies. Clin Cancer Res. 2018; 24(15):3539-3549. DOI: 10.1158/1078-0432.CCR-17-3831. View

17.

Hall M, Huelster H, Luckenbaugh A, Laviana A, Keegan K, Klaassen Z . Metastatic Hormone-sensitive Prostate Cancer: Current Perspective on the Evolving Therapeutic Landscape. Onco Targets Ther. 2020; 13:3571-3581. PMC: 7201221. DOI: 10.2147/OTT.S228355. View

18.

Loeb S, Folkvaljon Y, Robinson D, Franck Lissbrant I, Egevad L, Stattin P . Evaluation of the 2015 Gleason Grade Groups in a Nationwide Population-based Cohort. Eur Urol. 2015; 69(6):1135-41. PMC: 4909574. DOI: 10.1016/j.eururo.2015.11.036. View

19.

Oliveira K, Ramos I, Silva J, Barra W, Riggins G, Palande V . Current Perspectives on Circulating Tumor DNA, Precision Medicine, and Personalized Clinical Management of Cancer. Mol Cancer Res. 2020; 18(4):517-528. DOI: 10.1158/1541-7786.MCR-19-0768. View

20.

Stopsack K, Whittaker C, Gerke T, Loda M, Kantoff P, Mucci L . Aneuploidy drives lethal progression in prostate cancer. Proc Natl Acad Sci U S A. 2019; 116(23):11390-11395. PMC: 6561291. DOI: 10.1073/pnas.1902645116. View